Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2019-06-28
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, etoposide, and carboplatin, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer
growth in different ways. Some block the ability of cancer cells to grow and spread. Others
find cancer cells and help kill them or carry cancer-killing substances to them. Giving
colony-stimulating factors, such as G-CSF, helps stem cells move from the patient's bone
marrow to the blood so they can be collected and stored for peripheral stem cell transplant.
Giving more chemotherapy, such as cyclophosphamide, carmustine, and etoposide, and total-body
irradiation prepares the patient's bone marrow for the stem cell transplant. The stem cells
are then returned to the patient to replace the blood-forming cells that were destroyed by
the chemotherapy and radiation therapy. More radiation therapy is given after transplant to
kill any remaining cancer cells.
PURPOSE: This phase II trial is studying how well autologous peripheral stem cell transplant
works in treating patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.